pembrolizumab (keytruda) Report issue

Biologics mAb Orphan Drug FDA Approved FDA First in Class Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$3120.5825

United States

$3569.3400 - $4792.4300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

grapiprant and pembrolizumab | keytruda | lambrolizumab | mk-3475 | pembrolizumab | pemprolizumab | sch-900475

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue